Daily Diversion Prevention Insights
Practical, evidence-based insights for pharmacy diversion programs — updated daily.
Why Controlled Substance Counts Need Independent Verification
Rotate who performs routine counts so no one person always verifies the same drugs. Investigate every unexplained variance promptly, and watch for repeat discrepancies tied to the same shift or staff member.
DEA Registration Renewals: A Diversion Control Checkpoint
Track every DEA registration expiration on a shared calendar with early reminders, and confirm the renewal covers all registered locations and schedules. A lapse can quietly disrupt controlled substance handling.
Compounding Room Accountability: Close the Gaps
Reconcile every compounded batch against its source drug quantities, and require a documented reason and second-person review for any unexplained variance or waste, before the batch record is closed.
Closing the Loop on Post-Op Analgesia Audits
Compare post-op opioid dispenses against documented administrations and surgical end times. Patterns where one clinician repeatedly withdraws near case close, then wastes late, deserve prompt review.
Tamper-Evident Packaging: A Frontline Diversion Control
Treat any compromised seal, mismatched lot label, or resealed container as a reportable event, not a quiet fix. Document it immediately and quarantine the item, so tampering patterns show up in review.
Closing the Gap on Return-to-Stock Discrepancies
Treat every return-to-stock as a controlled transaction: require a second-person verification of drug, strength, and count, and routinely investigate items returned without a matching dispensing record.
Patient Complaints: An Overlooked Diversion Detection Signal
Track complaints about missing doses, 'short' fills, or pills that look different. Route them to your diversion lead, not just customer service, and trend by employee and shift to spot patterns.
Closing ADC Reporting Gaps Before They Hide Diversion
Check whether your ADC reports cover every override, discrepancy, and waste event, and who reviews them. A report nobody reads on a set schedule is a gap, however complete the data behind it.
Why Controlled Substance Counts Need Independent Verification
Counts done by the same person who handles the stock can hide shortages. Rotate who counts, require a second verifier on high-risk items, and investigate every unexplained variance immediately.
DEA Registration Renewals: A Hidden Diversion Control Point
Track every DEA registration expiration on a shared calendar with backup owners, and confirm renewal immediately. A lapsed registration can disrupt controlled substance ordering and invite unsafe workarounds.
Close the Loop on Every Compounding Room Batch
Reconcile every compounded batch from controlled substance issued to finished units, waste, and returns, with two signatures. Unexplained yield variances should trigger same-day review, never quiet adjustment.
Pharmacy Tech Access Controls: Least Privilege in Practice
Review tech access to controlled substance areas and systems regularly. Remove or adjust permissions promptly after role changes, and confirm no shared logins or unneeded override rights remain.
Reconciling Post-Op Analgesia Against Documented Pain Scores
Audit post-op opioid removals against documented pain assessments and reassessments. Staff who repeatedly pull doses with no matching pain score, or with no follow-up, merit a closer look.
Tamper-Evident Packaging as a Diversion Control Checkpoint
Treat any compromised seal, mismatched lot label, or resealed tote as a reportable event, not a nuisance. Log it immediately and quarantine the item so a diversion pattern isn't quietly absorbed.
Waste Documentation Is Only as Strong as the Witness
Check whether witnesses watch the actual waste event, not just sign afterward. Co-signatures added later, or by the same few people repeatedly, are a pattern worth reviewing.
Who Owns Your ADC Reports? Closing the Gaps
If your ADC reports only run on request, gaps hide in plain sight. Schedule recurring reviews of overrides, discrepancies, and unresolved waste, and confirm someone owns each report.
Why Controlled Substance Counts Need Independent Eyes
Have someone other than the person who handles a drug's receiving or dispensing perform counts, and investigate every variance immediately. Self-verified counts let small, repeated losses hide.
Keep DEA Registration Renewals Off the Last-Minute List
Track every DEA registration expiration on a shared calendar with early reminders and a named owner. A lapsed registration can disrupt controlled substance handling and invite improvised workarounds.
Closing the Accountability Gap in Compounding Rooms
Reconcile every compounding batch's controlled-substance usage against the master record, including yield and waste, before the record is closed. Unexplained variances should trigger review, not rounding.
Reconcile Post-Op Analgesia Against Documented Administration
Compare post-op opioid dispenses against documented administration and patient pain scores. Repeated gaps tied to one clinician or unit, especially after procedures, merit prompt, documented review.
Treat Broken Seals as Diversion Signals
Make every compromised seal, torn tamper-evident wrap, or resealed container a documented event with a named reviewer and a closed-loop follow-up—never just a quiet fix at the bench.
Return-to-Stock Discrepancies: Close the Gap Between Pull and Put-Back
Reconcile every return-to-stock against its original dispense or pull record daily. Unmatched returns, repeated returns by one person, or returns without a second-person check warrant immediate review.
Waste Documentation Only Works With a Real Witness
Check whether witnesses actually observe the waste or just co-sign afterward. Patterns of the same witness, or signatures after the fact, are warning signs worth reviewing against timestamps.
Treat Patient Complaints as a Diversion Detection Signal
Route patient complaints about short or altered controlled-substance fills to compliance, not just customer service, and compare each against dispensing and inventory records.
Closing the Gaps in ADC Reporting Coverage
Ask whether your ADC reports cover every override, discrepancy, and waste event, and whether anyone reviews them on a set schedule. Unreviewed or missing reports let patterns go unseen.
Controlled Substance Counts: Investigate Every Discrepancy Pattern
Don't just reconcile count variances, trend them. Repeated small discrepancies tied to the same shift, staff member, or drug often signal diversion that single-count reviews miss.
Review Pharmacy Tech Access Rights Regularly
Audit tech system permissions on a set schedule and whenever roles change. Access to controlled-substance functions should match current duties, with unused or outdated privileges removed immediately.
Post-Op Analgesia Audits: Reconcile Every Dose to Its Order
Audit post-op opioid dispensing against surgical end times, PACU records, and discharge orders. Repeated mismatches tied to one staff member or unit are a pattern to investigate, not a clerical error.
Why Return-to-Stock Reversals Deserve a Second Look
Before crediting a return to stock, verify the quantity and NDC match the original dispense — mismatches here are an easy, often-overlooked point for diversion to hide.
Turn Patient Complaints Into Diversion Red Flags
Track complaints about pain not controlled despite documented doses, missing medication, or early refill denials by patient—clusters tied to one staff member deserve review.
Closing the ADC Reporting Blind Spot
If your ADC discrepancy reports sit unreviewed for days, resolution becomes guesswork. Require same-day review of overrides, cancels, and late wastes—delay is where diversion hides.
Renewal Season Is a Diversion Blind Spot
DEA renewal deadlines can distract staff from routine counts and audits — schedule inventory reconciliation before and after the renewal window closes.
Compounding Room Access Needs a Real Audit Trail
If anyone can enter the compounding room without a logged badge swipe or witness signature, controlled substance waste and overfill are effectively unverifiable.
Locking Down Pharmacy Tech Access to Controlled Substances
Pharmacy tech access should be role-based and time-bound; audit login and override activity weekly, and revoke access immediately upon role change or termination.
Auditing Post-Op Analgesia Orders for Diversion Signals
Compare post-op opioid orders against documented pain scores and procedure type; frequent overrides, early refills, or standing PRN orders without titration notes deserve a closer look.
Closing the Loop on Return-to-Stock Discrepancies
Reconcile returned-to-stock quantities against the original dispensing record and the physical count before restocking, not after — discrepancies caught post-shelving are far harder to trace to a source.
Waste Documentation and Independent Witness Requirements
Wasting controlled substances alone, or with a witness who doesn't actually watch the syringe emptied and disposed of, defeats the control entirely. Require witnesses to observe the full waste event, not just co-sign afterward.
Patient Complaints: An Underused Diversion Signal
A pattern of complaints that a specific medication 'isn't working' or arrives short could signal tampering or substitution rather than a supply issue — route these reports to compliance, not just customer service.
DEA Renewal Lapses: A Hidden Diversion Blind Spot
A lapsed DEA registration for any prescriber or the pharmacy itself can silently disable controlled substance ordering checks—verify renewal dates 60 days out, not at expiration.
Compounding Room Accountability: Witness Every Waste Event
Require two staff to witness and sign every controlled-substance waste event in the compounding room—single-signature logs are the easiest control to falsify.
Auditing Pharmacy Tech Access to Controlled Substances
Review pharmacy tech system permissions regularly — access should match current job duties, and any override or unlock privilege beyond that scope is a red flag worth investigating immediately.
Audit Witness Pairing Patterns to Close Waste Documentation Gaps
Collusion risk rises when the same two employees consistently pair for waste witnessing. Audit co-signer combinations routinely — identical pairings may indicate a gap in your diversion prevention controls.
Patient Complaints: A Frequently Overlooked Drug Diversion Signal
Patient complaints about medications not working, missing doses, or receiving altered capsules can signal active diversion — route these reports to compliance, not just clinical staff.
Closing ADC Reporting Gaps Before Diversion Takes Root
ADC override transactions that go unreviewed for days create silent gaps where diversion hides. Verify your program reviews all unresolved discrepancies and overrides within a defined, documented timeframe.
Who Resolves Your Controlled Substance Count Discrepancies?
Consistent count discrepancies resolved by the same staff member are a red flag, not a coincidence. Audit who signs off on overages and shortages — the pattern matters more than the individual variance.
Verify Prescriber DEA Registrations on Every Controlled Substance Rx
Verify that prescriber DEA registrations on incoming controlled substance prescriptions are currently active — expired DEA numbers on Rx can indicate prescription fraud or active diversion.
Closing Accountability Gaps in the Compounding Room
Compounding rooms with controlled substances require documented ingredient reconciliation — every gram in should match every unit out. Unexplained yield variances are a red flag that warrants immediate investigation.
Auditing Pharmacy Tech Access to Controlled Substance Systems
Pharmacy technicians should have role-based access limited to their workflow area. Regularly audit whether tech credentials can access dispensing records beyond their assigned duties — shared logins mask accountability.
Post-Op Analgesia Audits: Spot Diversion Before It Escalates
During post-op analgesia audits, cross-reference documented pain scores against opioid administration records — consistent full-dose dispensing with low or absent pain documentation is a diversion red flag.
Auditing Return-to-Stock Entries to Catch Controlled Substance Diversion
Unwitnessed return-to-stock entries for controlled substances are a common diversion vector. Require dual verification and same-day wastage documentation to close this gap.
Blind Witnessing: A Hidden Gap in Waste Documentation
Blind witnessing — when a colleague signs off on waste without observing the disposal — is a common diversion gap. Confirm your policy requires the witness to be physically present and observe the full waste event.
Patient Complaints: An Overlooked Signal in Diversion Detection Programs
When patients report that their pain medication isn't working or that pills look different, these complaints may signal diversion. Route patient feedback systematically to your diversion program for review.
Closing the Loop on ADC Discrepancy Report Reviews
ADC discrepancy reports lose their value if reviewed weekly instead of daily — overrides and unwitnessed wastes compound quickly. Ask: who is accountable for reviewing each report, and how often?
Why Controlled Substance Count Reconciliation Stops Diversion Early
Unexplained count discrepancies — even small ones — can signal diversion. Review controlled substance count records daily and investigate any variance before the next shift ends.
Lapsed DEA Registrations: A Pharmacy Diversion Red Flag
Confirm prescriber DEA registrations are current before dispensing controlled substances. A lapsed registration may signal a provider who lost authority but continues writing — a classic diversion red flag.
Compounding Room Accountability: A Critical Drug Diversion Blind Spot
Compounding rooms require two-person verification for every controlled substance batch. Unexplained yield discrepancies between bulk ingredients used and finished product quantities are a key diversion warning sign.
Audit Pharmacy Tech Access Controls to Catch Diversion Early
Pharmacy techs should each have unique credentials scoped to their role — shared logins eliminate individual accountability and make it nearly impossible to trace diversion.
Spotting Diversion Through Post-Op Opioid Waste Audits
In post-op settings, compare administered opioid doses against patient pain scores — unexplained discrepancies or consistently high waste rates for specific providers may indicate diversion at the point of care.
Tamper-Evident Packaging: A First Line of Diversion Defense
Inspect tamper-evident seals on returned or wasted medications — broken, resealed, or swapped packaging is a known diversion indicator that visual checks alone may miss without documented verification.
Return-to-Stock Discrepancies: A Silent Controlled Substance Diversion Risk
When controlled substances are returned to stock without a witness signature or proper documentation, the gap creates an undetected diversion pathway. Audit RTS entries against dispensing records regularly.
Patient-Owned Medications: Closing the Verification and Diversion Gap
When patients bring medications from home, controlled substances in that supply are a diversion target — verify contents on admission, apply tamper-evident seals, and document any discrepancies immediately.
Patient Complaints: An Underutilized Drug Diversion Detection Signal
Patient complaints about inadequate pain relief — particularly recurring complaints tied to a specific dispenser or shift — can serve as an early indicator of drug diversion before any discrepancy appears in controlled substance logs. Diversion programs should establish a formal process for routing patient complaints about pain management to the pharmacy compliance team, not just clinical leadership. Reviewing whether complaint patterns correlate with specific staff, time periods, or patient populations adds a behavioral layer to detection that purely transactional audits often miss. Programs should ask themselves: do we have a mechanism to cross-reference patient grievance data against controlled substance administration records?
How does your program measure up?
Use the free DivertGuard assessment to score your hospital’s diversion prevention controls across 8 domains.
Run the free assessmentLast reviewed: September 2026 · Content is educational, not legal advice.